Back to search
FDAFDA · Food and drugs·Recall number D-333-2016

TRIMIX #2 (24 mg-0.8 mg-20 mcg /mL) Injection, 5 mL vials, Rx only, Essential Wellness PHARMACY, 4625 N. University, Peoria, IL 61614.

Published November 25, 2015 · Recall initiated: September 3, 2015

Summary

FDA records drug Class II recall D-333-2016, published November 25, 2015 and initiated September 3, 2015. Recalling firm: Kalman Health & Wellness, Inc. dba Essential Wellness Pharma; Status: Terminated; Reported quantity: 5 vials; Lot: Lot # 070815, Exp 09/08/2015; 071715, Exp 09/17/2015; 073115, Exp 10/012015; 080415, Exp 10/04/2015; and 080615, Exp 10/06/2015. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility: A recall of all compounded sterile preparations within expiry is being initiated due to observations associated with poor sterile production practices resulting in a lack of sterility assurance for their finished drugs.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Kalman Health & Wellness, Inc. dba Essential Wellness Pharma
Distributor
Nationwide
Lot
Lot # 070815, Exp 09/08/2015; 071715, Exp 09/17/2015; 073115, Exp 10/012015; 080415, Exp 10/04/2015; and 080615, Exp 10/06/2015
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was TRIMIX #2 (24 mg-0.8 mg-20 mcg /mL) Injection, 5 mL vials, Rx only, Essential Wellness PHARMACY, 4625 N. University, Peoria, IL 61614. recalled?

Yes. FDA published recall D-333-2016 on November 25, 2015. Reported hazard: Lack of Assurance of Sterility: A recall of all compounded sterile preparations within expiry is being initiated due to observations associated with poor sterile production practices resulting in a lack of sterility assurance for their finished drugs.

What should I do if I have this product?

Voluntary: Firm initiated · Letter